Tags

Type your tag names separated by a space and hit enter

Renoprotective effect of vildagliptin following hepatic ischemia/reperfusion injury.
Ren Fail. 2020 Nov; 42(1):208-215.RF

Abstract

Remote renal injury is a drastic consequence of hepatic ischemia/reperfusion (IR) injury. Vildagliptin (V) is a dipeptidyl peptidase-4 inhibitor that has a hepatorenal protective effect against models of liver and renal IR. This research was done to explore the protective role of vildagliptin against renal injury following hepatic IR injury as well as the possible involvement of transforming growth factor-beta (TGF-β)/Smad/alpha-smooth muscle actin (α-SMA) expressions in the pathophysiological mechanism of the remote renal injury. Three groups of male Wistar rats were organized into: sham group, IR group, and V + IR group in which 10 mg/kg/day of vildagliptin was pretreated for 10 days intraperitoneally. Blood in addition to renal and hepatic tissue samples was used for biochemical and histopathological studies. Hepatic IR induced a marked increase in serum creatinine, blood urea nitrogen, liver enzymes, renal nitric oxide, malondialdehyde, tumor necrosis factor-alpha levels with a marked upregulation of renal mRNA expressions of TGF-β, Smad2, Smad3, and α-SMA in addition to a marked decline in renal catalase content comparing to the sham group. Abnormal histopathological findings of hepatic and renal injury were detected in the IR group. Vildagliptin significantly improved these biochemical markers as well as the histopathological changes. The upregulation of renal TGF-β/Smad/α-SMA mRNA expressions was involved for the first time in the pathogenesis of the renal injury following hepatic IR and vildagliptin ameliorated this renal injury through blocking these expressions.

Authors+Show Affiliations

Emergency Hospital, Faculty of Medicine, Mansoura University, Mansoura, Egypt.College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.Chemistry Department, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32102588

Citation

Sherif, Iman O., et al. "Renoprotective Effect of Vildagliptin Following Hepatic Ischemia/reperfusion Injury." Renal Failure, vol. 42, no. 1, 2020, pp. 208-215.
Sherif IO, Alshaalan AA, Al-Shaalan NH. Renoprotective effect of vildagliptin following hepatic ischemia/reperfusion injury. Ren Fail. 2020;42(1):208-215.
Sherif, I. O., Alshaalan, A. A., & Al-Shaalan, N. H. (2020). Renoprotective effect of vildagliptin following hepatic ischemia/reperfusion injury. Renal Failure, 42(1), 208-215. https://doi.org/10.1080/0886022X.2020.1729189
Sherif IO, Alshaalan AA, Al-Shaalan NH. Renoprotective Effect of Vildagliptin Following Hepatic Ischemia/reperfusion Injury. Ren Fail. 2020;42(1):208-215. PubMed PMID: 32102588.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Renoprotective effect of vildagliptin following hepatic ischemia/reperfusion injury. AU - Sherif,Iman O, AU - Alshaalan,Alaa A, AU - Al-Shaalan,Nora H, PY - 2020/2/28/entrez PY - 2020/2/28/pubmed PY - 2020/11/28/medline KW - Hepatic ischemia/reperfusion KW - TGF-β KW - renal injury KW - vildagliptin KW - α-SMA SP - 208 EP - 215 JF - Renal failure JO - Ren Fail VL - 42 IS - 1 N2 - Remote renal injury is a drastic consequence of hepatic ischemia/reperfusion (IR) injury. Vildagliptin (V) is a dipeptidyl peptidase-4 inhibitor that has a hepatorenal protective effect against models of liver and renal IR. This research was done to explore the protective role of vildagliptin against renal injury following hepatic IR injury as well as the possible involvement of transforming growth factor-beta (TGF-β)/Smad/alpha-smooth muscle actin (α-SMA) expressions in the pathophysiological mechanism of the remote renal injury. Three groups of male Wistar rats were organized into: sham group, IR group, and V + IR group in which 10 mg/kg/day of vildagliptin was pretreated for 10 days intraperitoneally. Blood in addition to renal and hepatic tissue samples was used for biochemical and histopathological studies. Hepatic IR induced a marked increase in serum creatinine, blood urea nitrogen, liver enzymes, renal nitric oxide, malondialdehyde, tumor necrosis factor-alpha levels with a marked upregulation of renal mRNA expressions of TGF-β, Smad2, Smad3, and α-SMA in addition to a marked decline in renal catalase content comparing to the sham group. Abnormal histopathological findings of hepatic and renal injury were detected in the IR group. Vildagliptin significantly improved these biochemical markers as well as the histopathological changes. The upregulation of renal TGF-β/Smad/α-SMA mRNA expressions was involved for the first time in the pathogenesis of the renal injury following hepatic IR and vildagliptin ameliorated this renal injury through blocking these expressions. SN - 1525-6049 UR - https://www.unboundmedicine.com/medline/citation/32102588/Renoprotective_effect_of_vildagliptin_following_hepatic_ischemia/reperfusion_injury_ L2 - https://www.tandfonline.com/doi/full/10.1080/0886022X.2020.1729189 DB - PRIME DP - Unbound Medicine ER -